Drug Profile
Denosumab biosimilar - AryoGen Pharmed
Alternative Names: DyenixLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator AryoGen Pharmed
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postmenopausal osteoporosis
Most Recent Events
- 21 Oct 2020 Phase-III clinical trials in Postmenopausal osteoporosis are ongoing in Iran (SC) (NCT03293108)
- 29 Apr 2017 Phase-III clinical trials in Postmenopausal osteoporosis in Iran (SC) (NCT03293108)
- 12 Mar 2017 AryoGen Pharmed plans a phase III trial for Postmenopausal osteoporosis in Iran (SC, Injection) (IRCT2017020521315N9)